

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 794 174 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
10.09.1997 Bulletin 1997/37

(51) Int. Cl.⁶: **C07C 309/86**, **G01N 33/533**,
C07C 49/813

(21) Application number: **96116690.7**

(22) Date of filing: **17.10.1996**

(84) Designated Contracting States:
CH DE FI FR GB LI SE

(30) Priority: **08.03.1996 JP 51185/96**


(71) Applicants:
• **SUZUKI MOTOR CORPORATION**
Hamamatsu-shi, Shizuoka-ken (JP)
• **Matsumoto, Kazuko**
Kawasaki-shi, Kanagawa-ken (JP)

(72) Inventors:
• **Matsumoto, Kazuko**
Kawasaki-shi, Kanagawa-ken (JP)
• **Yuan, Jingli**
Itabashi-ku, Tokyo (JP)

(74) Representative: **Hansen, Bernd, Dr. Dipl.-Chem.**
et al
Hoffmann Eitle,
Patent- und Rechtsanwälte,
Arabellastrasse 4
81925 München (DE)

(54) **Labeled reagents for use in immunoassays and fluorescent compounds and complexes used therein**

(57) Disclosed are labeling reagents containing fluorescent compounds represented by the general formula



where n is a whole number. This labeling reagent has a high fluorescence emission intensity, gives high synthesis yield, permits both a solid-phase measurement and a liquid-phase measurement in immunoassays, and requires less measuring steps.

EP 0 794 174 A2

5 This invention relates to labeled reagents for use in time-resolved fluoroimmunoassay and other immunoassay techniques employed in the field of clinical examinations, and to fluorescent compounds and complexes used therein. The term "fluorescent compound" as used herein comprehends any compound that, when it is coordinated to a metal ion to form a complex, can produce fluorescence arising from the complex.

The labeling reagent used in the LKB system (i.e., an Eu chelate-labeled antibody) cannot produce fluorescence, whether it is used in the free state or in the state combined with a protein such as the antigen. In the LKB system, therefore, the concentration of the antigen is determined by adding a solution of 2-naphthoyltrifluoroacetone, tri-*n*-octylphosphine oxide and Triton X-100 as an enhancer to liberate Eu(III) in an aqueous solution, and then measuring the fluorescence produced by the resulting Eu(III) chelate micelles.

However, the LKB system has the following disadvantages. First, it is subject to contamination by surroundings (such as serum, reagents and air). Specifically, an excess of the enhancer needs to be added so as to react satisfactorily with Eu(III) liberated in an aqueous solution. Since this excess enhancer reacts with europium present in surroundings (such as air and serum), the concentration of the antigen may be overestimated. Secondly, since the fluorescent compound cannot produce fluorescence in the state combined with a protein such as an antigen or an antibody, the addition of an enhancing reagent is required during the course of the measuring procedure. Moreover, solid-phase measurements are not possible because the fluorescent compound is converted into a form capable of producing fluorescence only in an aqueous solution.

However, when an aromatic amine type labeling reagent is used, the fluorescence intensity is as low as 1/100 to 1/200 of that obtained with the LKB system using a β -diketone type reagent (i.e., 2-naphthoyltrifluoroacetone) as described above. Low fluorescence intensities do not permit highly sensitive determination of substances to be 30 assayed. That is, high detection limits prevent measurements down to a low concentration range. In order to enhance fluorescence intensity, an improved multilabeled reagent is disclosed in Japanese Patent Provisional Publication No. 88968/90. However, this reagent still fails to give a satisfactorily high fluorescence intensity.

35 However, the fluorescence intensities obtained with these labeling reagents are as low as about 1.4 times that obtained with the aromatic amine type labeling reagents in which the aforesaid BCPDA is used. Moreover, many steps are required for the synthesis thereof and the yield of the desired compound is low.

Accordingly, it is an object of the present invention to provide labeling reagents which have high fluorescence intensities, are cheaper than aromatic amine type labeling reagents (BCPDA type labeling reagents), give high synthesis yields, permit both solid-phase measurements and liquid-phase measurements, require less measuring steps so as to obtain measured results rapidly, and can be synthesized in a stable form permitting long-term storage, as well as fluorescent compounds and complexes used therein.

45 In order to accomplish the above object, the present invention provides fluorescent compounds represented by the general formula



where R is a group capable of combining with proteins, and n is a whole number; complexes composed of such fluorescent compounds and lanthanoid metal ions; and labeling reagents for use in immunoassays which contain such fluorescent compounds or such complexes.

The labeling reagents of the present invention can combine directly with proteins to be assayed (such as antigens and antibodies) and can produce fluorescence both in the free state and in the state combined with proteins.

Moreover, the labeling reagents of the present invention have a structure consisting of a β -diketone having attached thereto one or more electron-donating groups (aromatic ring substituent groups) and one or more electron-attracting groups (fluorine-substituted alkyl groups). Accordingly, they produce an intense fluorescence and have a long fluorescence lifetime. Their fluorescence emission intensities are more than about 10 times higher than those of fluorescent reagents used in the LKB system and more than about 1,000 times higher than those of aromatic amine type labeled reagents.

Moreover, the labeling reagents of the present invention can readily be synthesized in high yield. In particular, the pipetting of an enhancing reagent and the third incubation step, which are required in the conventional LKB system, are unnecessary. In addition, the well drying step required in measurements with conventional aromatic amine type labeling reagents is also unnecessary.

Moreover, in contrast to the LKB system, the labeling reagents of the present invention can produce fluorescence without liberating Eu(III) in an aqueous solution. Consequently, they are not subject to contamination by surroundings.

Moreover, they permit the measurement of immune complexes in both the solid phase and the liquid phase.


Furthermore, the labeling reagents of the present invention are stable substances which can be stored for a long period of time, and can be synthesized more cheaply than conventional aromatic amine type labeling reagents.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graph in which the logarithm of the concentration (M) of a bovine serum albumin (I)₃₅ solution is plotted as abscissa and the logarithm of the fluorescent count as ordinate.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

In the above general formula (1), R is a group capable of combining with proteins and so on. Specific examples thereof include the following groups:



where X is selected from halogen atoms, $-\text{OSO}_2\text{CH}_3$, $-\text{OSO}_2\text{F}$, $-\text{OSO}_2\text{CF}_3$, $-\text{SO}_2\text{C}_4\text{F}_9$ and



R^{A} is selected from alkyl, alkenyl, aryl and aralkyl groups, R^{B} is selected from alkylene, arylene and aralkylene groups, p is a whole number of 0 to 5, and q is a whole number of 2 to 10.

Among them, the chlorosulfonyl group ($-\text{SO}_2\text{Cl}$) is especially preferred because it has high reactivity with the amino groups of proteins and the like, and can be introduced into fluorescent compounds in a relatively easy way.

Specific examples of proteins and so on which can combine with R in the above general formula (1) include antibodies, biotin-labeled antibodies, antigens, avidin, streptavidin, bovine serum albumin, haptens, hormones, polypeptides, nucleic acids and polynucleotides.

In the above general formula (1), n is a whole number which is usually in the range of 1 to 6.

The lanthanoid metal ions which can be used in the present invention include, for example, ions of europium (Eu), samarium (Sm), terbium (Tb) and dysprosium (Dy).

The fluorescent compounds are synthesized in two steps. The first and second steps are separately described below.

First step


A β -diketone compound is synthesized by the Claisen condensation reaction of 4,4'-diacetyl-o-terphenyl with an ethyl perfluorocarboxylate.

Specific examples of the ethyl perfluorocarboxylate include ethyl trifluoroacetate, ethyl pentafluoropropionate, ethyl

heptafluorobutyrate and ethyl perfluoropentanoate.

A schematic diagram showing the synthesis path of the first step is given below. NaOCH_3 is a catalyst and dry ether is a solvent. The resulting product is purified by recrystallization. As the solvent for recrystallization, there may be used ethanol, 1,4-dioxane or a mixture thereof.

5




Second step

35


The chlorosulfonylation reaction of the synthesized β-diketone compound with chlorosulfuric acid is carried out to introduce the chlorosulfonyl group (ClSO_2) into the aromatic ring(s) of the β-diketone molecule. After completion of the reaction of chlorosulfuric acid with the β-diketone, unreacted chlorosulfuric acid is hydrolyzed in cold water. The chlorosulfonylated β-diketone precipitates without dissolving in cold water. A schematic diagram showing the synthesis path of the second step is given below.

40



The fluorescent compounds can be synthesized according to the above-described steps. The labeling of proteins is carried out by an amide-forming reaction between chlorosulfonyl groups and amino groups. This reaction proceeds easily in a carbonate buffer solution (pH 9.0-9.5) at room temperature. A schematic diagram showing the path for the

synthesis of labeled proteins is given below.



Immunoassays using the labeling reagents of the present invention include, for example, time-resolved fluoroimmunoassay and specific combination assays. Time-resolved fluoroimmunoassay is a highly sensitive fluoroimmunoassay in which a long-life fluorescent label (such as an Eu chelate) is used to measure only the fluorescence signal of the label in a time-resolved fluorometric manner after the background fluorescence having a short lifetime has disappeared. Specific combination assays comprehend immunoassays utilizing an antigen-antibody reaction, assays utilizing a receptor-acceptor combination reaction, assays utilizing the hybridization of nucleic acids, and the like.

Examples

Synthesis of 4,4'-diacetyl-o-terphenyl

An example using 4,4'-diacetyl-o-terphenyl as an acetylated aromatic ring compound is given below. First of all, the method for the synthesis of 4,4'-diacetyl-o-terphenyl is described.


A solution of 100 mmol of o-terphenyl in 100 ml of CH_2Cl_2 was slowly added dropwise to a stirred solution of 210 mmol of AlCl_3 and 205 mmol of CH_3COCl in 200 ml of CH_2Cl_2 at 0°C . This mixture was stirred at 0°C for 30 minutes and then at room temperature for 24 hours. The reaction mixture was further refluxed for 2 hours and poured into ice/hydrochloric acid (conc.). After this mixture was fully stirred, CH_2Cl_2 was removed by vacuum distillation. The precipitate was separated by filtration and washed thoroughly with water. The product was recrystallized from about 250 ml of 2-butanone, and the needle crystals so formed were separated by filtration and vacuum-dried. Thus, 22.1 g of the product was obtained in a 70.3% yield. The results of elemental analysis were as follows:

Elemental analysis:		
Calcd. (%):	C, 84.05;	H, 5.77.
Found (%):	C, 84.06;	H, 5.87.


It was confirmed by $^1\text{H-NMR}$ that the product was the desired compound.

Synthesis of intermediate (j') of fluorescent compound (j)

The method for the synthesis of the following compound (j')



which is an intermediate for the preparation of fluorescent compound (j) represented by the following formula



is described below.

15 To 30 g of dry ether (Et₂O) were added 3.0 g of NaOCH₃, 10 mmol of 4,4'-diacetyl-o-terphenyl and 20 mmol of C₃F₇COOC₂H₅. This mixture was sealed at room temperature and stirred for 24 hours. The dry ether was removed by distillation (or evaporation), and the resulting solid was vacuum-dried for 30 minutes. After the product was neutralized with 100 ml of 15% sulfuric acid, the resulting precipitate was separated by filtration and washed thoroughly with water. The precipitate was dissolved in 200 ml of ethanol by the application of heat, and the resulting solution was filtered to
20 remove insoluble matter therefrom. This solution was concentrated under reduced pressure to about 20 ml, and slowly added dropwise to 200 ml of stirred petroleum ether. After this mixture was fully stirred, the small amount of precipitate so formed was removed by filtration and the filtrate was concentrated under reduced pressure to remove all organic solvent therefrom. The resulting oil was vacuum-dried to obtain a yellow powder. This yellow powder was thoroughly washed with petroleum ether and then vacuum-dried for 24 hours. Thus, 4.60 g of the product was obtained in a 65.0%
25 yield.

30

Elemental analysis:		
Calcd. (%):	C, 51.00;	H, 2.28.
Found (%):	C, 51.22;	H, 2.61.

Calcd. (%):	C, 51.00;	H, 2.28.
Found (%):	C, 51.22;	H, 2.61.

35 It was confirmed by ¹H-NMR that the product was the desired compound.

Preparation of fluorescent compound (j)

40 2 mmol of β-diketone (j') was slowly added to 3.5 ml of stirred chlorosulfuric acid at room temperature. After this mixture was stirred at room temperature for 7 hours, the reaction mixture was carefully and slowly added dropwise to 150 ml of stirred water/ice (using external cooling with ice/water). The resulting precipitate was quickly separated by centrifugation, washed with cold water (at about 5°C), and centrifuged twice. Using a small amount of cold water, the precipitate was transferred to a glass filter and freed of water by suction filtration. The chlorosulfonylated β-diketone so formed was vacuum-dried at room temperature for 48 hours or more. Its yields was 77%.

45

Elemental analysis:		
Calcd. (%):	C, 44.76;	H, 1.88.
Found (%):	C, 44.50;	H, 1.92.

Calcd. (%):	C, 44.76;	H, 1.88.
Found (%):	C, 44.50;	H, 1.92.

50 It was confirmed by ¹H-NMR that the product was the desired compound.

55 Labeling of a protein with the fluorescent compound (j)

The labeling of bovine serum albumin (BSA) with fluorescent compound (j) is described below.
50 mg of BSA was dissolved in 10.00 ml of a 0.1 mol/L carbonate buffer solution (pH 9.3). Then, 2 ml of a DMF

solution containing fluorescent compound (j) in the same molar amount as the amino groups present in bovine serum albumin (59 -NH₂ groups per molecule) was slowly added dropwise to the stirred BSA solution at room temperature. After this mixture was stirred at room temperature for an hour, the labeled BSA and the hydrolyzate of unreacted fluorescent compound were separated by gel filtration. In this separation step using a gel column (Sephadex G-50, 1.0 x 29.1 cm), a 0.05 mol/L aqueous solution of ammonium hydrogen carbonate (pH 8.0) was used as the developing solvent. The flow rate was 1 ml per 90 seconds and the effluent was collected as 1 ml fractions. Since a satisfactory separating effect would not be achieved by separating 10 ml of the solution at a time under these column conditions, 5 ml portions of the solution were separated. Fractions containing the labeled BSA were combined and dialyzed against water at 4°C overnight to remove inorganic salts therefrom. Using the solution before gel filtration, its absorbance at 330 nm was measured. Then, the molar absorption coefficient at 330 nm of the fluorescent compound was calculated from the molar concentration of the fluorescent compound used and the absorbance at 330 nm. The molar absorption coefficient so calculated was $3.41 \times 10^4 \text{ mol}^{-1}\text{cm}^{-1}\text{L}$, and there was no absorption of bovine serum albumin at 330 nm. On the assumption that the molar absorption coefficient does not change during the process of the labeling reaction, the label concentration in the labeled BSA solution and the labeling ratio of BSA to label were calculated. The labeling ratio of BSA to the fluorescent compound in the labeled BSA fraction obtained in the above-described manner was about 35.

Labeling of streptavidin and avidin with fluorescent compound (j)

The labeling of streptavidin (SA) and avidin (AD) with the aforesaid fluorescent compound (j) is described below.

To 1.5 mg of the aforesaid fluorescent compound (j) was added a solution of 5 mg of streptavidin (or avidin) in 1.1 ml of a 0.1 mol/L carbonate buffer solution (pH 9.1) and 25 µL of DMF. After this mixture was stirred at room temperature for two hours, the insoluble matter was separated by centrifugation. The precipitate was washed with 2.0 ml of a 0.05 mol/L Tris-HCl buffer solution (pH 7.7) and centrifuged. The two supernatants were combined and dialyzed twice against 4 L of a solution containing 0.1 mol/L of NaHCO₃ and 0.25 g of NaN₃ at 4°C (for 16 hours and for 6 hours, respectively). The labeling ratio of protein to the fluorescent compound in the labeled protein solution obtained in this manner was about 10.

Labeling of anti-mouse IgG(H+L) sheep antibody with fluorescent compound (j)

2 ml of a 2 mg/ml solution of anti-mouse IgG(H+L) sheep antibody was dialyzed twice against 3 L of physiological saline at 4°C for 24 hours, and adjusted to pH 9.2 with a 0.5 mol/L Na₂CO₃ solution. Then, 2.0 mg of the aforesaid fluorescent compound (j) was added to the antibody solution and 125 µL of DMF was added thereto with stirring. After this mixture was stirred at room temperature for an hour, 50 µL more of DMF was added thereto and the resulting mixture was stirred again at room temperature for an hour. The insoluble matter was separated by centrifugation, and the supernatant was dialyzed twice against 4 L of a solution containing 0.1 M NaHCO₃ and 0.25 g of NaN₃ at 4°C for 24 hours. The labeling ratio of protein to the fluorescent compound in the labeled protein solution obtained in this manner was about 11.

It was confirmed by application to practical immunoassays that the labeled proteins obtained in the above-described manner retained their physiological activities.

Method for the measurement of fluorescence intensities and results

The method for the measurement of fluorescence intensities was the same as described above for fluorescent compound (b).

Fluorometric measurements were made with a Hitachi F-4500 fluorescence spectrophotometer (manufactured by Hitachi Ltd.) using a 150W xenon lamp as the excitation light source. Prior to measurements, the spectral characteristics of the excitation side spectrometer (200 to 600 nm) and the like were corrected by using Rhodamine B as a light quantum meter, and the spectral characteristics of the fluorescence side spectrometer (200 to 600 nm), the spectral characteristics of the detector, and the like were corrected by using a diffusion element. Fluorescence lifetimes were measured with an instrument consisting of the combination of an LPX100 Excimer Laser pulsed light source (pulse half-width < 10 ns, 10 Hz; manufactured by Lambda Physik) and an HR320 spectrometer (manufactured by SPEX). Specifically, changes in fluorescence intensity attending changes in delay time were measured and the fluorescence lifetime τ was calculated according to the following equation.

$$\ln I(t) = \ln I(0) - t/\tau$$

Time-resolved fluorometric measurements were made with a Cyber Fluor 615 time-resolved fluorophotometer, and samples were excited with a 337.1 nm nitrogen laser to measure fluorescence intensities at 615 nm. The measuring conditions included a delay time of 200 µs and counting times of 200 to 600 µs. The measuring wells comprised white

opaque polystyrene wells (manufactured by Dynatech Laboratories).

Each fluorescent compound was dissolved in an organic solvent such as acetone, methanol or ethanol. Then, using an EuCl_3 solution, fluorescent compound- Eu^{3+} standard solutions were prepared and their fluorescence intensities were measured. The results are shown in TABLE 1.

TABLE 1

Fluorescent compound	λ_{ex} (nm)	λ_{em} (nm)	Fluorescence intensity ($10^3 \text{ cm}^{-1}\text{m}^{-1}$)
LKB system (conventional technique)	339	610	12.16
j [*]	340	610	About 150

Fluorescence characteristics of a labeled BSA solution in the presence of europium(III)

The addition of an EuCl_3 solution to a β -diketone-labeled BSA solution yields an intensely fluorescent solution. Using a $\text{BSA(j)}_n\text{-Eu}^{3+}$ solution so prepared, its fluorescence spectrum, the influence of pH and buffer solutions on its fluorescence intensity, and its fluorescence lifetime were measured.

The fluorescence spectrum of a $\text{BSA(j)}_n\text{-Eu}^{3+}$ solution was as follows.

In Tris-HCl:

$\lambda_{\text{ex.max}} = 326 \text{ nm}$

$\lambda_{\text{em.max}} = 611.6 \text{ nm}$ (half-width, about 9 nm)

In carbonate buffer solution:

$\lambda_{\text{ex.max}} = 324 \text{ nm}$

$\lambda_{\text{em.max}} = 611.6 \text{ nm}$ (half-width, about 9 nm)

In phosphate buffer solution:

$\lambda_{\text{ex.max}} = 324 \text{ nm}$

$\lambda_{\text{em.max}} = 611.6 \text{ nm}$ (half-width, about 9 nm)

In topo-SDS- NaHCO_3^* solution:

$\lambda_{\text{ex.max}} = 334 \text{ nm}$

$\lambda_{\text{em.max}} = 613.4 \text{ nm}$ (half-width, about 9 nm)

The results of measurement of the influence of pH and buffer solutions on the fluorescence intensity of the $\text{BSA(j)}_n\text{-Eu}^{3+}$ solution and of its fluorescence lifetime are shown in TABLE 2.

(* A $1.0 \times 10^{-5} \text{ mol/L}$ topo-0.05% SDS-0.1 mol/L NaHCO_3 solution)

TABLE 2

Buffer solution	0.1 mol/L Tris-HCl					0.1 mol/L carbon-ate	0.1 mol/L phos-phate	1.0 x 10 ⁻⁵ mol/L topo-0.05% SDS 0.1 mol/L NaHCO ₃
pH	7.2	7.8	8.5	9.1	9.9	9.3	9.0	8.4
Relative fluores-cence intensity	75	89	97	100	100	44	16	321
Fluorescence life-time	261 μs							395 μs
*λ _{ex} = 337 nm. Measured solution: BSA(j) ₃₅ -Eu ³⁺ , [BSA(j) ₃₅] = 1.8 x 10 ⁻⁸ mol/L, [Eu ³⁺] = 1.0 x 10 ⁻⁶ mol/L.								

It can be seen from TABLE 2 that the fluorescent intensity depends on the pH of the solution and the composition of the buffer solution. An intense fluorescence was produced in a Tris-HCl solution. The fluorescence was relatively weaker in a carbonate buffer solution and significantly weaker in a phosphate buffer solution. Moreover, in a solution of topo having high coordination power to Eu³⁺, the fluorescence was much more intense owing to the powerful "synergic effect" of topo. At the same time, a slight increase in fluorescence lifetime was observed. It was confirmed by experiment that the fluorescence of the solution was not affected by the oxygen dissolved therein.

Time-resolved fluorometry of labeled BSA solutions

Using a BSA(j)₃₅ solution obtained as above, a 1.0 x 10⁻⁵ mol/L topo-0.05% SDS-0.1 mol/L NaHCO₃ solution, and a 1.0 x 10⁻⁵ mol/L EuCl₃ solution, a BSA(fluorescent compound)₃₅-Eu³⁺ standard solution (2.8 x 10⁻¹⁴ mol/L) was prepared. At the same time, a series of solutions were prepared by fixing the Eu³⁺ concentration at 1.0 x 10⁻⁶ mol/L and varying the BSA(fluorescent compound)₃₅ concentration. The prepared solutions were allowed to stand at room temperature for 2 hours and then subjected to time-resolved fluorometry. Measurements were made by pipetting each solution (having an identical concentration) into 4 wells (300 μ l per well), and the average of the measured values was regarded as the measured value (I). Similarly, the solvent was pipetted into 4 wells and the average of the measured values was regarded as the background (I₀). The (I-I₀) values thus obtained were used as fluorescent counts to construct a working curve. The results are shown in FIG. 1. From FIG. 1, the detection limit of fluorescent compounds (j) was determined to be 1.3 x 10⁻¹² mol/L.

Using a time-resolved fluorophotometer ("Cyber Fluor 615"), the detection sensitivity of the labeled reagent of the present invention (i.e., the labeled BSA-Eu³⁺) was compared with those of conventional techniques (i.e., the LKB system and an aromatic amine type labeled reagent). It can be seen from TABLE 3 that the labeled reagent of the present invention is several tens of times as sensitive as the LKB system and several thousand times as sensitive as the aromatic amine type labeled reagent using BCPDA as the fluorescent compound.

TABLE 3

	Detection limit of fluores- cent compound (mol/L)
LKB system	5.0 x 10 ⁻¹¹
BCPDA	1.0 x 10 ⁻⁸
j	1.3 x 10 ⁻¹²

Time-resolved fluoroimmunoassay of human alpha-fetoprotein (AFP) using polyclonal antibodies and SA-BHHCT-Eu³⁺ labelLabeling of streptavidin with the fluorescent compound (j)

To 1.5 mg of the fluorescent compound (j) (BHHCT) was added a solution of 5 mg of streptavidin (SA) in 1.1 ml of a 0.1 mol/L carbonate buffer (pH 9.1) and 25 μ L of DMF solution. After this mixture was stirred at room temperature for 2 to 4 hours, the insoluble matter was separated by centrifugation. The precipitate was washed with 2 ml of a 0.05 mol/L Tris-HCl buffer solution (pH 7.8) and centrifuged. The two supernatants were combined and dialyzed against 4 L of a solution containing 0.1 mol/L of NaHCO₃ and 0.25 g of NaN₃ at 4°C twice (for 16 hours and for 6 hours, respectively). After dialyzation, a small amount of insoluble matter was removed by centrifugation. 10 mg of bovine serum albumin (BSA) and 2 mg of NaN₃ were added to the labeled SA solution. The labeled SA solution was adjusted to about pH 6.0 to 6.5 with 0.1 mol/L of HCl. The volume of the obtained solution was about 4 ml. The solution was cloudy, but was preserved as it was. The solution was divided into 100 μ L portions and was preserved at -20°C. Before the labeled SA was used in immunoassay, its solution was diluted to one three hundredth (1/300) of the original concentration with a 0.05 mol/L of Tris-HCl (pH 7.8) solution which contains 1 % of BSA, 0.9 % of NaCl, 0.05 % of NaN₃ and 1.0×10^{-6} M of EuCl₃, was allowed to stand overnight at 4 °C or heat at 50 °C for two hours and thereafter was used. Little change was observed after the diluted solution was preserved for two weeks at 4 °C. The labeled SA could be preserved for a long period of time when it was preserved at -20 °C.

Time-resolved fluoroimmunoassay

The fraction of anti-human AFP goat IgG was diluted with a 0.1 mol/L of carbonate buffer solution (pH 9.6) to decrease the concentration of the antibody to 2.5 μ g/ml. The obtained solution was pipetted into 96 wells of a microtiter plate (100 μ L per well) and was allowed to stand overnight at 4 °C. The solution was removed by suction. The wells were washed with a 0.01 mol/L of phosphate buffer-0.05 % of Tween 20 solution twice and with a 0.01 mol/L of phosphate buffer solution (pH 7.4) once. A 1 % of BSA-2 % of sucrose-0.05 % of NaN₃-0.1 mol/L of NaHCO₃ buffer solution (pH=8.3) was pipetted into the wells (100 μ L per well), was allowed to stand at room temperature for an hour and was washed with the above-described phosphate buffer solution. These steps are a coating step and a blocking step of wells. The plate could be preserved for a long period of time (for example, one and a half months) at -20 °C.


Human AFP standard solution was diluted with a 1 % of BSA-0.05 % of NaN₃-0.9 % of NaCl-0.01 mol/L of phosphate buffer (pH 7.4) solution to a series of solutions with concentrations ranging from 10⁴ ng/ml to 10⁻⁶ ng/ml. The diluted solutions were pipetted into the wells (50 μ L per well) and were incubated for an hour at 37°C. The solutions were removed by suction, and the wells were washed with phosphate buffer. Rabbit anti-human AFP IgG solution, which had been diluted to one five hundredth (1/500) of the original concentration with a 1 % of BSA-0.05 % of NaN₃-0.9 % of NaCl-0.01 mol/L of phosphate buffer solution, was pipetted into the wells (50 μ L per well) and was allowed to stand for an hour at 37°C. After the solution was removed by suction and the wells were washed, a biotinylated goat anti-rabbit IgG (H+L) solution which had been diluted to one hundredth (1/100) of the original concentration was pipetted into wells (50 μ L per well) and was allowed to stand for an hour at 37°C. After the solution was removed and the wells were washed with a physiological saline solution once, the SA-BHHCT-Eu³⁺ solution was pipetted into the wells (50 μ L per well) and was allowed to stand for an hour at 37°C. After the solution was removed and the wells were washed with a physiological saline-0.05 % of Tween 20 solution three times and with a 0.1 mol/L of Tris-HCl-0.05 % of Tween 20 solution (pH=8.5) five times, the solid-phase measurements of the fluorescence were made. A 1.0×10^{-5} mol/L of topo-0.05 % of SDS- 1.0×10^{-6} mol/L of EuCl₃-0.1 mol/L of NaHCO₃ solution was pipetted into the wells (50 μ L per well) and was allowed to stand for an hour at 50°C. When the temperature of the solution reached to room temperature, the fluorescence of the solution was measured. The results of the solid-phase measurements are shown in Fig. 2. The results of the measurements after dissolution are shown in Fig. 3.

Sensitivity of AFP immunoassay using SA-BHHCT-Eu³⁺

The detection limit in solid-phase measurements was 10⁻⁵ ng/ml. It corresponds to 1.4×10^{-16} mol/L or 7.1×10^{-21} mol/assay (50 μ L). The detection limit after dissolution was 10⁻⁶ ng/ml. It corresponds to 1.4×10^{-17} mol/L or 7.1×10^{-22} mol/assay (50 μ L). The coefficient of variation in measurements was less than 10 %. The detection limit of AFP immunoassay using conventional horse radish peroxidase (HRP)-avidin was 1 ng/ml.


Claims

1. A fluorescent compound of the general formula



where R is a group capable of combining with proteins, and n is a whole number.


- 15
2. A complex composed of a fluorescent compound as claimed in claim 1 and a lanthanoid metal ion.
 3. A labeling reagent for use in immunoassays which contains a fluorescent compound as claimed in claim 1.
 4. A labeling reagent for use in immunoassays which has a complex moiety as claimed in claim 2.
- 20
5. A fluorescent compound of the general formula



where n is a whole number.

- 35
6. A complex composed of a fluorescent compound as claimed in claim 5 and a lanthanoid metal ion.
- 40
- 45
- 50
- 55

FIG.1



$$y = 14.228 + 0.98x, \quad R = 1.0$$

FIG. 2





FIG. 3



正本

裝

訂

線

經濟部智慧財產局專利核駁審定書

受文者：科學技術振興事業團（代理人：陳長文先生）

地址：臺北市松山區敦化北路二〇一號七樓

發文日期：中華民國九十二年十二月十一日
發文字號：（九二）智專二（五）15130字

第〇九二二一二五八〇九〇號

- 一、申請案號數：〇八九一二〇一〇一
- 二、發明名稱：高感度免疫測定法
- 三、申請人：

名稱：科學技術振興事業團

地址：日本

- 四、專利代理人：

姓名：陳長文先生

地址：臺北市松山區敦化北路二〇一號七樓

- 五、申請日期：八十九年十月二十五日
- 六、優先權項目：

專利分類 IPC(7) : G01N 33/533

! 4
8 6





I 1999/09/29 日本11-277629

七、審查人員姓名：劉正民 委員

八、審定內容：

主文：本案應不予專利。


依據：專利法第二十條第一項第一款、第二十條第二項、第二十條第一項前段、第二十二條第四項。

理由：

(一) 本案所請為一種偵測生物流體樣品中之組織介素的方法，其中由一連串具有親和力的物質交互連結，最後由螢光訊號檢測其中組織介素的量。申請專利範圍共16項，其中申請專利範圍第1項所請之「時間分析形螢光受疫測定 (TR-FIA) 法」，已揭露於JP6024450中，其中第1項中之(D)，利用鏈抗生素蛋白或抗生物素蛋白形成共軛物之部份已為一般人廣為應用，另第1項中之(e)利用鑷系金屬離子作為螢光偵測，已揭露於EP0794174，不符專利要件。

(二) 申請專利範圍第16項所請之『套組』，其實質之技術內容與申請專利範圍第1項重複，且未將套組之相關溶液、成份比例、配方具體敘明，實難使熟悉該項技術者瞭解，並可據以實施，不符專利要件。

(三) 申請專利範圍中『約』為不明確之用語，應予以修正或刪除。



據上論結，本案不符法定專利要件，爰依專利法第二十條第一項第一款、第二十條第二項、第二十條第一項前段、第二十二條第四項，審定如主文。

局長
蔡練生

依照分層負責規定授權單位主管決行

如不服本審定，得於文到之次日起三十日內，備具再審查理由書一式二份及規費新台幣陸仟元整（專利說明書及圖式合計在五十頁以上者，每五十頁加收新台幣五百元，其不足五十頁者以五十頁計），向本局申請再審查。